MariMed Strikes Licensing Deal to Bring Edibles Line to New York Market

NORWOOD – MariMed Inc. has signed a licensing agreement with Farm 2 Hand, LLC, a licensed cultivator and processor in New York, to roll out its lineup of edibles across the state starting in 2026.

Under the pact, Farm 2 Hand will handle manufacturing and distribution for MariMed’s key brands, including Betty’s Eddies fruit chews, Bubby’s Baked goods, and InHouse gummies. The deal calls for MariMed to design and outfit a dedicated kitchen at Farm 2 Hand’s facility in the Bronx. Financial details remain under wraps.

The move marks MariMed’s first foray into New York, a market valued at $6 billion in potential sales and drawing operators from across the country. “This opens up our brands to one of the largest adult-use markets in the nation,” said Jon Levine, MariMed’s CEO. He highlighted the agreement’s role in building wholesale channels and leveraging New York’s media spotlight to amplify national recognition for the company’s offerings.

MariMed, which operates in eight states including Illinois, Ohio, and Maryland, has leaned on brand licensing to extend its reach without the burden of full-scale infrastructure builds. The strategy has paid off in places like Virginia, where similar deals have fueled double-digit revenue gains for its edibles segment over the past year. New York’s regulatory hurdles [still easing after the state’s 2021 legalization] have slowed some expansions, but recent approvals for processors like Farm 2 Hand signal smoother paths ahead.

For Farm 2 Hand, this partnership adds well-known brands to its portfolio at a time when the number of adult-use dispensaries in New York State is passing 500. The Bronx kitchen could position the company as a go-to hub for premium edibles, tapping into consumer demand for flavored, low-dose options that have driven category growth nationwide.

As MariMed eyes further licensing opportunities in high-potential states, this New York entry underscores a deliberate push toward brand dominance over asset-heavy growth. In a sector where margins often squeeze under compliance costs, such alliances offer a lean way to capture market share, and MariMed’s track record suggests they could deliver steady returns for years to come.